UroGen Pharma Ltd.: 10-Q filed 2026-08-05
What UroGen Pharma Ltd. reported in its quarterly report filed 2026-08-05 (fiscal Q2 2026): 42 published measures, 114 facts as tagged in accession 0001437749-26-025794.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2026-08-05
- Fiscal period
- fiscal Q2 2026
- Accession
- 0001437749-26-025794 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All UroGen Pharma Ltd. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 252,590,000 | USD | |
| At 2025-12-31 | 200,455,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 384,986,000 | USD | |
| At 2025-12-31 | 305,929,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | -132,396,000 | USD | |
| At 2026-03-31 | -124,253,000 | USD | |
| At 2025-12-31 | -105,474,000 | USD | |
| At 2025-06-30 | -93,376,000 | USD | |
| At 2025-03-31 | -46,458,000 | USD | |
| At 2024-12-31 | -8,803,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 79,133,000 | USD | |
| At 2025-12-31 | 110,745,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -14,351,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -37,925,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | -49,940,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -93,783,000 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | -78,322,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | -81,849,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 114,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 185,000 | USD | 181 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 72,456,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 123,415,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 24,215,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 44,469,000 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 65,704,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 330,000 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | -19,015,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 2,443,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | -997,641,000 | USD | |
| At 2025-12-31 | -959,716,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 50,380,112 | shares | 91 |
| 2026-01-01 to 2026-06-30 | 50,282,221 | shares | 181 |
| 2025-04-01 to 2025-06-30 | 47,739,816 | shares | 91 |
| 2025-01-01 to 2025-06-30 | 47,582,610 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -0.28 | USD/shares | 91 |
| 2026-01-01 to 2026-06-30 | -0.75 | USD/shares | 181 |
| 2025-04-01 to 2025-06-30 | -1.05 | USD/shares | 91 |
| 2025-01-01 to 2025-06-30 | -1.97 | USD/shares | 181 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 5,629,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 857,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 1,015,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 1,407,000 | USD | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 597,000 | USD | |
| At 2025-12-31 | 637,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 9,958,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 5,802,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 111,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -20,152,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | -41,448,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -78,362,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 235,426,000 | USD | |
| At 2025-12-31 | 186,024,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 61,915,000 | USD | |
| At 2025-12-31 | 46,418,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 15,472,000 | USD | |
| At 2025-12-31 | 12,137,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 88,757,000 | USD | |
| At 2025-12-31 | 33,082,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 24,589,000 | USD | |
| At 2025-12-31 | 16,464,000 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 65,884,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 112,704,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 20,665,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 38,589,000 | USD | 181 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 6,572,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 10,711,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 3,550,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 5,880,000 | USD | 181 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 48,437,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 99,923,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 43,199,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 78,166,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 17,336,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 32,933,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 18,914,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 38,785,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 48,869,530 | shares | |
| At 2025-12-31 | 48,350,272 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | -2,000 | USD | |
| At 2025-12-31 | 19,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 2,810,000 | USD | |
| At 2025-12-31 | 3,080,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 3,044,000 | USD |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 200,000,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 5,337,000 | USD | |
| At 2025-12-31 | 5,224,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 4,740,000 | USD | |
| At 2025-12-31 | 4,587,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 8,761,000 | USD | |
| At 2025-12-31 | 5,161,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2026-06-30 | 12,776,000 | USD | |
| At 2025-12-31 | 14,672,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -8,722,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -37,068,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | -48,925,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -92,376,000 | USD | 181 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -14,361,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -37,946,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | -49,948,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -93,833,000 | USD | 181 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | 100,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | 153,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | 100,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | 152,000 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-04-01 to 2026-06-30 | -347,000 | USD | 91 |
| 2026-01-01 to 2026-06-30 | -670,000 | USD | 181 |
| 2025-04-01 to 2025-06-30 | -378,000 | USD | 91 |
| 2025-01-01 to 2025-06-30 | -468,000 | USD | 181 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 339,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | 220,000 | USD | 181 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 55,675,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | -653,000 | USD | 181 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2026-01-01 to 2026-06-30 | 8,125,000 | USD | 181 |
| 2025-01-01 to 2025-06-30 | -2,099,000 | USD | 181 |
Inspect the source
- Entity
- UroGen Pharma Ltd. / CIK 0001668243
- Captured
- 2026-09-21T17:22:34.317Z
- SEC response SHA-256
c0f9fceebc685f0377739af490e9f9cff0a1b4a6e8cf3110d6b22e5d217158cf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001668243.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))